Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

26 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins.
Sharma P, Butters CJ, Smith V, Elsby R, Surry D. Sharma P, et al. Among authors: elsby r. Eur J Pharm Sci. 2012 Aug 30;47(1):244-55. doi: 10.1016/j.ejps.2012.04.003. Epub 2012 Apr 19. Eur J Pharm Sci. 2012. PMID: 22538052
Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States.
Birmingham BK, Bujac SR, Elsby R, Azumaya CT, Zalikowski J, Chen Y, Kim K, Ambrose HJ. Birmingham BK, et al. Among authors: elsby r. Eur J Clin Pharmacol. 2015 Mar;71(3):329-40. doi: 10.1007/s00228-014-1800-0. Epub 2015 Jan 30. Eur J Clin Pharmacol. 2015. PMID: 25630984 Clinical Trial.
Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
Birmingham BK, Bujac SR, Elsby R, Azumaya CT, Wei C, Chen Y, Mosqueda-Garcia R, Ambrose HJ. Birmingham BK, et al. Among authors: elsby r. Eur J Clin Pharmacol. 2015 Mar;71(3):341-55. doi: 10.1007/s00228-014-1801-z. Epub 2015 Feb 12. Eur J Clin Pharmacol. 2015. PMID: 25673568 Clinical Trial.
Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R, Martin P, Surry D, Sharma P, Fenner K. Elsby R, et al. Drug Metab Dispos. 2016 Mar;44(3):398-408. doi: 10.1124/dmd.115.066795. Epub 2015 Dec 23. Drug Metab Dispos. 2016. PMID: 26700956
Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions.
Elsby R, Smith V, Fox L, Stresser D, Butters C, Sharma P, Surry DD. Elsby R, et al. Xenobiotica. 2011 Sep;41(9):764-83. doi: 10.3109/00498254.2011.578761. Epub 2011 May 25. Xenobiotica. 2011. PMID: 21612343
The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672.
Elsby R, Gillen M, Butters C, Imisson G, Sharma P, Smith V, Surry DD. Elsby R, et al. Drug Metab Dispos. 2011 Feb;39(2):275-82. doi: 10.1124/dmd.110.035881. Epub 2010 Nov 12. Drug Metab Dispos. 2011. PMID: 21075975 Clinical Trial.
In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate.
Elsby R, Fox L, Stresser D, Layton M, Butters C, Sharma P, Smith V, Surry D. Elsby R, et al. Eur J Pharm Sci. 2011 May 18;43(1-2):41-9. doi: 10.1016/j.ejps.2011.03.006. Epub 2011 Apr 1. Eur J Pharm Sci. 2011. PMID: 21440623
Mechanistic in vitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine.
Elsby R, Chidlaw S, Outteridge S, Pickering S, Radcliffe A, Sullivan R, Jones H, Butler P. Elsby R, et al. Pharmacol Res Perspect. 2017 Oct;5(5):e00357. doi: 10.1002/prp2.357. Pharmacol Res Perspect. 2017. PMID: 28971610 Free PMC article.
Mechanistic In Vitro Studies Indicate that the Clinical Drug-Drug Interaction between Telithromycin and Simvastatin Acid Is Driven by Time-Dependent Inhibition of CYP3A4 with Minimal Effect on OATP1B1.
Elsby R, Hare V, Neal H, Outteridge S, Pearson C, Plant K, Gill RU, Butler P, Riley RJ. Elsby R, et al. Drug Metab Dispos. 2019 Jan;47(1):1-8. doi: 10.1124/dmd.118.083832. Epub 2018 Oct 22. Drug Metab Dispos. 2019. PMID: 30348903
Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1.
Elsby R, Hilgendorf C, Fenner K. Elsby R, et al. Clin Pharmacol Ther. 2012 Nov;92(5):584-98. doi: 10.1038/clpt.2012.163. Epub 2012 Oct 10. Clin Pharmacol Ther. 2012. PMID: 23047648 Review.
26 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback